Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924455 · ClinicalTrials.gov registry record
HBV-HIV Coinfection Research Network
A clinical trial, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 139
- Enrollment target
NCT01924455: Completed study, sponsored by Virginia Commonwealth University.
NCT01924455 is a clinical trial that has completed, run by Virginia Commonwealth University. The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01924455 has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 139 participants
- Enrollment target
Study Summary
Despite effective ART that can suppress both HIV and HBV, HBV-related liver disease remains a significant co-morbidity in this population. Little is known about the histologic spectrum of liver disease, the significance of complete vs. incomplete HBV suppression, the utility of novel virologic and serum markers of disease severity, and the long-term renal and bone effects of TDF-based therapy. This proposal will address these important questions and impact the science and health of those coinfected with HBV-HIV.
Primary Outcome
We will clinically, histologically, serologically, and virologically characterize a well-defined cohort of HBV-HIV patients in North America in a cross-sectional manner
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2014-04 |
| Est. Completion | 2019-03-31 |
What the finished NCT01924455 record still lists
NCT01924455 is an observational study that tracks outcomes without assigning an intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01924455 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01924455 about?
NCT01924455 is a clinical study titled "HBV-HIV Coinfection Research Network". Despite effective ART that can suppress both HIV and HBV, HBV-related liver disease remains a significant co-morbidity in this population. Little is known about the histologic spectrum of liver disease, the significance of complete vs. incomplete HBV suppression, the utility of novel virologic and s...
What is the current status of trial NCT01924455?
This trial is currently completed. The enrollment target is 139 participants. The study started on 2014-04. Estimated completion is 2019-03-31.
Who is sponsoring clinical trial NCT01924455?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia